標靶藥物、免疫治療、生物製劑的前眼部副作用

The Side Effects of Target Therapy, Immunotherapy, and Biologics on External Eye

楊瑞瀚(Jui-Han Yang) ； 吳若玄(Jo-Hsuan Wu) ； 蕭靜熹(Ching-Hsi Hsiao)

《台灣醫學》 25卷4期 (2021/07) Pp. 499-502

https://doi.org/10.6320/FJM.202107_25(4).0008

摘要

如同前面的文章所提及，標靶藥物、免疫治療、生物製劑雖然帶來許多治療新契機，但其全身性治療卻亦會造成眼部方面許多副作用。「前眼部」由於其特殊生理及結構，也會受到這些藥物的影響。在此，我們將會討論這類新穎的治療如何造成「前眼部」的副作用，及其臨床上的處置。

關鍵字

標靶藥物 ； 免疫治療 ； 生物製劑 ； 前眼部

並列摘要

Over the past decades, there has been an increase in the use of novel treatment options such as targeted therapy, immunotherapy and biologics, particularly in oncology practice. Although these agents are thought to be more specific and less toxic than traditional cytotoxic chemotherapy, they are associated with a variety of toxicities, including ocular side effects due to their specific targeting activities in the eye. In this article, we discussed the proposed pathogenesis, monitoring guidelines, and management recommendations for the adverse events of these agents on external eye. Collaboration between oncologists and ophthalmologists is essential to diagnose and treat these side effects promptly.

並列關鍵字

targeted therapy ； immunotherapy ； biologics ； external eye

參考文獻

Jeremy Chung Bo Chiang, Ilyanoon Zahari, Maria Markoulli, et al. The impact of anticancer drugs on the ocular surface. Ocul Surf 2020;18:403-17.

Goel V, Raina S, Chandragouda D, et al. Trichomegaly of eyelashes after treatment with erlotinib in carcinoma pancreas. Int J Trichology 2014;6:23-4.

Wang SB, Lei KJ, Liu JP, et al. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review. Oncol Lett 2015;10:954-6.

Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology 2012;119:1798-802.

Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008;27:612-4.